Maze Therapeutics Ownership | Who Owns Maze Therapeutics?


OverviewRevenueFinancialsChart

Maze Therapeutics Ownership Summary


Maze Therapeutics is owned by 88.56% institutional investors, 11.49% insiders. Trv gp iv is the largest institutional shareholder, holding 13.85% of MAZE shares.

MAZE Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockMaze Therapeutics88.56%11.49%-0.05%
SectorHealthcare Stocks 486.50%11.08%-397.59%
IndustryBiotech Stocks 304.14%11.08%-215.23%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Trv gp iv6.07M13.85%$74.53M
Frazier life sciences management4.57M10.42%$56.04M
Arch venture management4.12M9.40%$50.59M
Deep track capital, lp3.95M9.01%$48.45M
Matrix capital management company, lp2.49M5.67%$30.51M
Alphabet2.41M5.50%$29.60M
Foresite capital management iv2.11M4.82%$25.91M
Ah capital management1.70M3.88%$20.89M
General catalyst group management1.04M2.36%$12.71M
Trv gp v950.80K2.17%$11.67M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Trv gp iv6.07M45.63%$74.53M
Foresite capital management iv2.11M20.93%$25.91M
Arch venture management4.12M16.91%$50.59M
Matrix capital management company, lp2.49M13.69%$30.51M
Trv gp v950.80K7.04%$11.67M
Ah capital management1.70M6.67%$20.89M
Foresite capital management v345.19K5.25%$4.24M
Frazier life sciences management4.57M2.24%$56.04M
Deep track capital, lp3.95M1.55%$48.45M
Alphabet2.41M1.39%$29.60M

Top Buyers

HolderShares% AssetsChange
Deep track capital, lp3.95M1.55%679.78K
Frazier life sciences management4.57M2.24%438.27K
Driehaus capital management193.40K0.02%61.28K
Blackrock funding, inc. /de614.70K0.00%32.12K
Congress wealth management llc / de /30.23K0.00%30.23K

Top Sellers

HolderShares% AssetsChange
Logos global management lp611.91K0.83%-325.00K
Affinity asset advisors---250.00K
Casdin capital758.86K0.85%-187.50K
Ikarian capital262.74K0.62%-60.00K
Boothbay fund management75.53K0.02%-21.44K

New Positions

HolderShares% AssetsChangeValue
Congress wealth management llc / de /30.23K0.00%30.23K$370.98K
Alps advisors23.58K0.00%23.58K$289.29K
Ensign peak advisors18.54K0.00%18.54K$227.47K
Virtus investment advisers6.94K0.03%6.94K$85.15K
Eversource wealth advisors114.000.00%114.00$1.40K

Sold Out

HolderChange
Comerica bank-636.00
Corebridge financial-4.33K
Davidson kempner capital management lp-13.67K
Oxford asset management llp-17.00K
Affinity asset advisors-250.00K

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20257415.63%38,836,4378.98%880.57%42-34.38%13-
Mar 31, 202567-40,037,113-139-67---

Insider Transactions Trends


DateBuySell
2025 Q3--

MAZE Ownership FAQ


Who Owns Maze Therapeutics?

Maze Therapeutics shareholders are primarily institutional investors at 88.56%, followed by 11.49% insiders and -0.05% retail investors. The average institutional ownership in Maze Therapeutics's industry, Biotech Stocks , is 304.14%, which Maze Therapeutics falls below.

Who owns the most shares of Maze Therapeutics?

Maze Therapeutics’s largest shareholders are Trv gp iv (6.07M shares, 13.85%), Frazier life sciences management (4.57M shares, 10.42%), and Arch venture management (4.12M shares, 9.40%). Together, they hold 33.66% of Maze Therapeutics’s total shares outstanding.

Does Blackrock own Maze Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Maze Therapeutics.

Who is Maze Therapeutics’s biggest shareholder by percentage of total assets invested?

Trv gp iv is Maze Therapeutics’s biggest shareholder by percentage of total assets invested, with 45.63% of its assets in 6.07M Maze Therapeutics shares, valued at 74.53M$.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools